PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer

2 Views
administrator
administrator
07/14/23

Prof Fabrice Barlesi speaks to ecancer about the ESMO 2020 virtual congress concerning a first analysis of the PIONeeR study.

This involved precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients treated with PD1/L1 immune checkpoint inhibitors (ICIs).

Prof Barlesi outlines the aims of the trial, to understand these PD1 inhibitors. He explains what the trial found, and what this means for the future of NSCLC treatment.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next